Cleveland BioLabs, Inc: Genome Protection Announces Publication of the Next Generation Deimmunized TLR5 Agonist, GP532
The substantially improved pharmacological profile of GP532 opens new opportunities for broader therapeutic applications of this class of pharmaceuticals
BUFFALO, NY / ACCESSWIRE / April 14, 2021 / Genome Protection, Inc. (GPI), a joint venture between Cleveland BioLabs, Inc. (NASDAQ:CBLI) and Everon BioSciences, LLC, an innovative biopharmaceutical company focused on developing medical interventions to prevent and treat aging and age-related diseases, announces a publication in
Communications Biology, a journal of
Nature portfolio
, describing the creation, properties and preclinical validation of efficacy of a new deimmunized and pharmacologically optimized Toll-like receptor 5 (TLR5) agonist, named GP532.
Cleveland BioLabs, Inc Announces Closing of $14 Million Registered Direct Offering of Common Stock
pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.
Cleveland BioLabs : Announces Closing of $14 Million Registered Direct Offering of Common Stock
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.